Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165841 · ClinicalTrials.gov registry record · Phase 2
Maintenance Intermittent Therapy for Symptomatic GERD Patients
A Phase 2 study of Gastroesophageal Reflux Disease, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00165841: Completed Phase 2 study of Gastroesophageal Reflux Disease, sponsored by Eisai.
NCT00165841 is a Phase 2 study of Gastroesophageal Reflux Disease that has completed, run by Eisai. The registered enrollment target is 200 participants, below the 348-participant average among 25 other Gastroesophageal Reflux Disease trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00165841, a Phase 2 study of Gastroesophageal Reflux Disease, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study to determine the efficacy of 20 mg of rabeprazole given as a maintenance intermittent therapy following acute treatment for Symptomatic Gastroesophageal Reflux Disease (s-GERD).
Primary Outcome
The percentage of heartburn-free days during the 6-month Maintenance Treatment Phase in patients treated with rabeprazole 20 mg compared to patients who received placebo in the ITT Population. Heartburn-free day was defined as no heartburn in both the daytime and nighttime period on a given day. Note a total 388 subjects were enrolled at the beginning of Acute Phase and 200 subjects were enrolled into the double-blind 6-month maintenance treatment phase.
Conditions Studied
Interventions
- DRUG Rabeprazole 20 mg
Study Locations (1)
California
- Quality Care Medical Center Inc. - Vista
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2004-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
What the finished NCT00165841 record still lists
NCT00165841 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 348-participant average among 25 other Gastroesophageal Reflux Disease trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Gastroesophageal Reflux Disease appearing as the primary indexed condition, and to 1 intervention - of which Rabeprazole 20 mg is the first listed.
NCT00165841 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00165841 about?
NCT00165841 is a clinical study titled "Maintenance Intermittent Therapy for Symptomatic GERD Patients". The purpose of this study to determine the efficacy of 20 mg of rabeprazole given as a maintenance intermittent therapy following acute treatment for Symptomatic Gastroesophageal Reflux Disease (s-GERD).
What is the current status of trial NCT00165841?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2004-10. Estimated completion is 2008-06.
What conditions does trial NCT00165841 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux Disease.
What interventions are being tested in trial NCT00165841?
The interventions under investigation include: Rabeprazole 20 mg (DRUG).
Who is sponsoring clinical trial NCT00165841?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00165841 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00165841's enrollment target sits among peer trials
200 7th of 25 higher than 18 of 25 other Gastroesophageal Reflux Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroesophageal Reflux Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
COMPLETED · Phase 2
-
A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)
COMPLETED · Phase 2
-
Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
COMPLETED · Phase 2
-
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
COMPLETED · Phase 2
-
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia